The re-emergence of direct-to-consumer genetic health risk tests has healthcare providers worried once again about their impact and utility.
23andMe can again sell its direct-to-consumer genetic health risk tests after obtaining FDA authorization.
Following the premarket authorization of 23andMe's tests, the agency may allow other firms to sell similar tests DTC without having to submit them for review.
The company has developed a suite of initial products focused on ancestry that will compete with offerings from 23andMe, AncestryDNA, and Family Tree DNA.
The companies will recruit and track a cohort of women to study environmental, genetic, and lifestyle factors that may contribute to fertility outcomes.
A South Carolina TV station employee gets differing results from direct-to-consumer genetic tests.
Andy Page is leaving his position as president of 23andMe, Recode reports.
The project is the consumer genomics firm's latest effort to improve diversity in genetics research.
The firm said the panel will help include African Americans in health-focused genetic research, which has been skewed towards people with European ancestry.
Living DNA can break down the origins of a customer’s ancestry into 21 distinct regions within Britain alone, as well as across 80 different worldwide populations.
The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.
A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.
The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.
In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.